Confluence Investment Management LLC Has $289,000 Stock Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Confluence Investment Management LLC boosted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 400.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,290 shares of the company’s stock after buying an additional 14,632 shares during the period. Confluence Investment Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $289,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in shares of Dr. Reddy’s Laboratories by 3.4% in the second quarter. Renaissance Technologies LLC now owns 1,995,495 shares of the company’s stock worth $152,037,000 after acquiring an additional 65,606 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Dr. Reddy’s Laboratories by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after purchasing an additional 114,294 shares in the last quarter. State Street Corp raised its stake in Dr. Reddy’s Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock valued at $72,292,000 after purchasing an additional 16,641 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 59.4% in the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after purchasing an additional 183,146 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Dr. Reddy’s Laboratories by 30.8% in the third quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock worth $32,530,000 after buying an additional 96,339 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Barclays reduced their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Price Performance

RDY opened at $15.44 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 1 year low of $13.43 and a 1 year high of $16.89. The stock has a fifty day moving average price of $14.78 and a 200 day moving average price of $15.49. The stock has a market cap of $12.89 billion, a price-to-earnings ratio of 24.66 and a beta of 0.53.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.